Loading...
Novel targets in aggressive lymphoma
Targeting CD20 with the monoclonal antibody rituximab has improved survival in patients with aggressive B-cell lymphomas, the majority of which are cured with chemoimmunotherapy. Patients progressing through or relapsing after their treatment have a poor prognosis. Despite a number of promising nove...
Na minha lista:
| Udgivet i: | Hematology Am Soc Hematol Educ Program |
|---|---|
| Hovedforfatter: | |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
American Society of Hematology
2020
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7727526/ https://ncbi.nlm.nih.gov/pubmed/33275737 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/hematology.2020000093 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|